In vivo最新文献

{"title":"Perfusion Instability During Hyperthermic Intraperitoneal Chemotherapy: The Utility of a Problem-solving Flowchart.","authors":"Chiara Soligo, Carola Cenzi, Francesca Foscaro, Beatrice Bordignon, Susanna Savi, Paolo Perdonò, Gianni Munaretto, Francesca Visentin, Tommaso Tarantino, Alberto Cerato, Pierluigi Pilati, Roberta Cabianca, Antonio Sommariva","doi":"10.21873/invivo.13810","DOIUrl":"10.21873/invivo.13810","url":null,"abstract":"<p><strong>Background/aim: </strong>During hyperthermic intra-peritoneal chemotherapy (HIPEC), perfusion instability (PI) is defined as the inability to maintain a proper perfusion flow without impairment of the target temperature. The management and resolution of this adverse event is underreported and poorly investigated. The study aimed to evaluate the incidence of PI during closed cytoreductive surgery (CRS)-HIPEC and how a problem-solving approach might limit the effects of this adverse event.</p><p><strong>Patients and methods: </strong>A retrospective analysis of patients who underwent CRS-HIPEC at our Institution was performed. PI was defined when the patient's outflow pressure of the circuit was not able to maintain target flow and temperature (1,100 ml/min and 41°C). A step-by-step problem-solving flowchart, which included checking the drain position, proper muscle relaxation, changing the bed position, adjusting the perfusion volume and switching the drain flow switch, was used.</p><p><strong>Results: </strong>A total of 208 HIPEC procedures were reviewed between May 2018 and January 2023. PI occurred in 21 cases (10.1%). Patients with PI had a significantly longer perfusion time (p<0.001). Although the mean outflow pressure and flow rate were significantly lower in patients with PI (p<0.001), the target temperature was maintained until the end of HIPEC.</p><p><strong>Conclusion: </strong>A scheduled problem-solving approach by HIPEC perfusionist team was able to resolve most cases of PI. Further research on perfusion technical details and volume calculation is needed to prevent and limit the effects of this complication.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"127-131"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Costal Cartilage Fractures on CT Images With Computer-aided Detection System for Rib Fractures.","authors":"Amiko Kayo, Nanae Tsuchiya, Koji Yonemoto, Masato Nakamura, Sadayuki Murayama, Masaki Uechi, Shota Kinjo, Masaki Sato, Hidekazu Moromizato, Shun Toyosato, Fumikiyo Ganaha, Yuka Kawakami, Takashi Matayoshi, Akihiro Nishie","doi":"10.21873/invivo.13840","DOIUrl":"10.21873/invivo.13840","url":null,"abstract":"<p><strong>Background/aim: </strong>Costal cartilage fractures are associated with poor prognosis in patients with blunt chest trauma. A Computer-Aided Detection (CAD) system for detecting rib fractures has been used in practice, but it is unclear whether this system recognizes costal cartilage fractures. This study investigated whether the CAD system for rib fracture can detect costal cartilage fractures.</p><p><strong>Patients and methods: </strong>A total of 89 patients with costal cartilage fractures from participating hospitals over an 18-year period were included in the study. The presence of a costal cartilage fracture was determined by three radiologists. We reviewed fracture location, cartilage calcification, dislocation, and callus formation. The percentage of agreement between the radiologists and the CAD system (Rib fracture CAD, Fujifilm Medical Co., Ltd) was assessed.</p><p><strong>Results: </strong>We detected 246 costal cartilage fractures in 89 patients. The costal cartilage of rib 7 was injured most frequently. Costal cartilage fractures were categorized as either mid-chondral, costochondral, or chondro-sternal. The CAD system detected 33 lesions; 16 were consistent with the costal cartilage fractures determined by the radiologists (costochondral junction 13, mid-chondral 2, chondro-sternal 1).</p><p><strong>Conclusion: </strong>The CAD system for rib fracture can detect costal cartilage fractures at the costochondral junction but is not sufficiently sensitive to detect costal cartilage fractures without calcification. The CAD system for rib fracture needs further development before it can be used to detect rib cartilage fractures.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"390-395"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio.","authors":"Minehiko Inomata, Naoki Takata, Zenta Seto, Nozomu Murayama, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui","doi":"10.21873/invivo.13850","DOIUrl":"10.21873/invivo.13850","url":null,"abstract":"<p><strong>Background/aim: </strong>Chemoimmunotherapy has improved overall survival in patients with extensive small-cell lung cancer (SCLC). However, the backgrounds of patients enrolled in clinical trials tend to differ from those of patients treated in clinical practice, and the effectiveness of chemoimmunotherapy may be unclear in some populations, including patients with poor performance status. This study aimed to evaluate the effectiveness of chemoimmunotherapy for SCLC patients in clinical practice while focusing on several subgroups.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the data of SCLC patients who received chemoimmunotherapy or chemotherapy. The association between chemoimmunotherapy and overall survival was evaluated by adjusting for patient backgrounds using the Cox proportional hazards model, followed by a subset analysis.</p><p><strong>Results: </strong>The chemoimmunotherapy and chemotherapy groups included 43 and 71 patients, respectively. The Cox proportional hazards model showed that chemoimmunotherapy was significantly associated with improved overall survival (hazard ratio=0.47, 95% confidential interval=0.26-0.83). Furthermore, subgroup analysis showed that overall survival was significantly improved in patients with good performance status, lower neutrophil/lymphocyte ratio, and no liver metastases. However, overall survival with chemoimmunotherapy was similar to that with chemotherapy and was less than 12 months in patients with a poor performance status or higher neutrophil/lymphocyte ratio.</p><p><strong>Conclusion: </strong>Chemoimmunotherapy was significantly associated with improved overall survival in clinical practice. However, the effectiveness was equivocal in SCLC patients with a poor performance status or higher neutrophil/lymphocyte ratio.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"467-472"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Contribution of Epithelial Growth Factor Receptor to PI3K/AKT Pathway Dysregulation in Canine Soft Tissue Sarcoma.","authors":"Alfarisa Nururrozi, Masaya Igase, Kyohei Miyanishi, Masashi Sakurai, Yusuke Sakai, Mika Tanabe, Takuya Mizuno","doi":"10.21873/invivo.13808","DOIUrl":"10.21873/invivo.13808","url":null,"abstract":"<p><strong>Background/aim: </strong>Soft tissue sarcoma (STS) is a mesenchymal tumor affecting multiple organs in dogs. Previous studies identified activation of the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (PKB, AKT) pathway in canine STS cell lines and clinical samples, but the underlying mechanism remains unclear. This study investigated PTEN loss, PIK3CA mutation, and EGFR over-expression as potential drivers of PI3K/AKT pathway activation in STS.</p><p><strong>Materials and methods: </strong>We analyzed 36 canine STS samples. PTEN and EGFR expression were evaluated using immunohistochemistry, while PIK3CA and EGFR mutations were assessed through DNA sequencing.</p><p><strong>Results: </strong>PTEN was expressed in all analyzed samples, with no evidence of loss. Weak PTEN expression was observed in 12 (33.3%) samples, while 24 (66.7%) showed normal expression. DNA sequencing of PIK3CA revealed a single point mutation (c.554 A>C, H554P) in one case, but no hotspot mutations were identified. High EGFR expression was significantly correlated with elevated phospho-AKT levels (p<0.0001). Immunolabelling indicated that 30 samples (83.3%) were EGFR-positive, and 27 of these also showed positive phospho-AKT labeling. Accordingly, one missense point mutation in exon 21 of EGFR (E868K) was identified in one of 12 samples.</p><p><strong>Conclusion: </strong>EGFR over-expression, rather than PTEN loss or PIK3CA mutations, may contribute to PI3K/AKT pathway dysregulation in canine STS. Further studies with larger sample sizes and additional validation techniques are necessary to confirm these findings.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"110-119"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Brain Development in Children With Congenital Diaphragmatic Hernia - an Automated Brain Segmentation Approach.","authors":"Sherif A Mohamed, Larissa Götz, Victor Saase, Julia Elrod, Jonathan Endlein, Meike Weis, Eva Neumaier-Probst","doi":"10.21873/invivo.13828","DOIUrl":"10.21873/invivo.13828","url":null,"abstract":"<p><strong>Background/aim: </strong>Congenital diaphragmatic hernia (CDH) is a critical condition affecting newborns, which often results in long-term morbidities, including neurodevelopmental delays, which affect cognitive, motor, and behavioral functions. These delays are believed to stem from prenatal and postnatal factors, such as impaired lung development and chronic hypoxia, which disrupt normal brain growth. Understanding the underlying mechanisms of these neurodevelopmental impairments is crucial for improving prognosis and patient outcomes, particularly as advances in treatments like ECMO have increased survival rates but also pose additional risks for neurodevelopment. This study aimed to evaluate brain development in 2-year-old children who underwent CDH repair, with and without ECMO, compared to healthy controls using an MRI-based automated segmentation approach.</p><p><strong>Patients and methods: </strong>The study included 31 children with CDH, of which 10 received ECMO therapy, and a control group of 31 healthy children. MRI-examinations were performed using a 3-T system. MRI data were processed using the CerebroMatic toolbox and SPM12 software to measure cerebrospinal fluid (CSF), gray matter (GM), white matter (WM), and cortical thickness (CT).</p><p><strong>Results: </strong>Patients with CDH showed significantly increased volumes of CSF (p=0.009), GM (p=0.02), and total intracranial volume (TIV) (p=0.01), compared to healthy controls. ECMO-treated patients had significantly increased GM (p=0.01) and CSF (p=0.005) volumes in comparison to healthy controls. CT was significantly higher in CDH patients regardless of ECMO therapy, indicating potential maturational deficits.</p><p><strong>Conclusion: </strong>The study reveals neurodevelopmental differences in children with CDH, particularly in those requiring ECMO therapy. Increased CT, GM, and CSF volumes suggest complex neurodevelopmental challenges.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"302-310"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Hypnotics, Accidents, and Injuries: A Study Based on the Adverse Drug Event Reporting Database in Japan.","authors":"Rintaro Sogawa, Masakazu Hatano, Fumi Nishimura, Junya Nishi, Ayaka Matsuoka, Kota Shinada, Haruna Yamada, Hiroshi Tateishi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe","doi":"10.21873/invivo.13846","DOIUrl":"10.21873/invivo.13846","url":null,"abstract":"<p><strong>Background/aim: </strong>The use of hypnotic drugs can lead to accidents and injuries. However, few reports have shown their association with these events after adjusting for many concomitant medications. This study aimed to determine whether the use of hypnotic drugs was associated with accidents and injuries.</p><p><strong>Patients and methods: </strong>Using the Japanese Adverse Event Reporting Database, 772,387 reports published between September 2023 and April 2004 were analyzed. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) for accidents and injuries associated with each hypnotic drug were calculated after adjusting for potential confounders.</p><p><strong>Results: </strong>Of the total, 12,484 reports indicated association of hypnotic drugs with accidents and injuries. The use of each hypnotic drug was associated with accidents, injuries, and other adverse events. However, a multivariate analysis adjusted for age, sex, reporting year, and concomitant medications showed a considerable decrease in ROR for melatonin receptor agonists (adjusted ROR=1.26; 95%CI=1.03-1.55) and dual orexin receptor antagonists (DORAs) (adjusted ROR=1.04; 95%CI=0.86-1.25). Particularly in DORAs, a loss of signal for accidents and injuries was observed.</p><p><strong>Conclusion: </strong>The risk of accidents and injuries may vary with hypnotic drug use; however, DORAs may be less frequently associated with these events. The results of this study provide useful information for the selection of hypnotic drugs.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"433-439"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3-Bromo-4,5-dihydroxybenzaldehyde Attenuates Allergic Contact Dermatitis by Generating CD4⁺Foxp3⁺ T cells.","authors":"Sang-Chul Han, Jung-Il Kang, Youn Kyung Choi, DA Hee Yang, Ki Ju Kim, Ha Jeong Boo, Weon-Jong Yoon, Hee-Kyoung Kang, Eun-Sook Yoo, Hye-Jin Boo","doi":"10.21873/invivo.13818","DOIUrl":"10.21873/invivo.13818","url":null,"abstract":"<p><strong>Background/aim: </strong>Regulatory T cells (Tregs) play a crucial role in inflammatory responses by regulating the activity of various immune cells. M2 macrophages induced by IL-10 and TGF-β exhibit anti-inflammatory functions and induce Treg differentiation. Although the beneficial effects of 3-bromo-4,5-dihydroxybenzaldehyde (BDB) on various diseases have been widely reported, the mechanisms, through which it alleviates allergic contact dermatitis (ACD) via Tregs and macrophages, are not well understood. Therefore, this study aimed to explore whether BDB suppresses ACD and induces Treg generation.</p><p><strong>Materials and methods: </strong>Mice were sensitized with 1% dinitrochlorobenzene (DNCB), followed by the application of 0.3% DNCB to their ears every 3 days for 31 days. BDB (100 mg/kg) was administered orally once daily throughout the 31 days. Cytokine and transcription factor expression were analyzed via real-time PCR and western blotting, while CD4⁺Foxp3⁺ T cell differentiation and T cell proliferation were evaluated using flow cytometry.</p><p><strong>Results: </strong>BDB exhibited therapeutic efficacy in mice with ACD. In this study, the administration of BDB promoted the upregulation of transforming growth factor beta (TGF-β)-dependent CD4⁺Foxp3⁺ T cells. BDB elicited T cell hypo-responsiveness and suppressed the expression of cytokines related to the Th1, Th2, and Th17 cell subsets. BDB-M2 macrophages directly mediated the differentiation of CD4⁺Foxp3⁺ T cells from CD4⁺ T cells and concurrently suppressed the proliferation of CD4⁺ T cells.</p><p><strong>Conclusion: </strong>BDB augments M2 macrophage function and induction of Tregs confers effective protection against ACD in mice. Consequently, BDB may represent a promising therapeutic approach for the treatment of inflammatory skin diseases.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"201-209"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in miRNA Pattern Expression Associated With COVID-19 Severity.","authors":"Paola B Zárate-Segura, Macario Martínez-Castillo, Aarón Paris Garduño-Gutiérrez, J Manuel Hernández-Hernández, Luis Javier Cano-Martínez, Jaime García-Mena, Ramón M Coral-Vázquez, Fernando Bastida-González","doi":"10.21873/invivo.13852","DOIUrl":"10.21873/invivo.13852","url":null,"abstract":"<p><strong>Background/aim: </strong>Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, manifests a wide range of clinical symptoms ranging from mild to moderate and severe. Host-related factors influence the course of SARS-CoV-2 infection; for instance, the expression of host microRNAs (miRNAs) could influence the progression and complications of COVID-19. This study aimed to determine the expression pattern of endogenous miRNAs in 80 severe COVID-19 patients compared to a group of healthy individuals.</p><p><strong>Materials and methods: </strong>The miRNA screening expression analysis was performed using TaqMan Low-Density Array, and the expression changes of miR-490-3p, miR-195-5p, miR-454-3p, and miR-431-5p were validated using RT-qPCR. In silico analysis was used to identify new targets and predict the pathways, biological processes, and interactions of the selected miRNAs.</p><p><strong>Results: </strong>The miR-490-3p, miR-195-5p, miR-454-3p, and miR-431-5p, were over-expressed in the total population of severe COVID-19 patients compared to the control group. miR-490-3p was found to be over-expressed in both female and male COVID-19 patients.</p><p><strong>Conclusion: </strong>Specific miRNAs might be a potential biomarker for predicting the clinical course of COVID-19.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"482-490"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutations of the CEACAM5 Gene PELPK Motif in Patients With Appendiceal or Colorectal Adenocarcinoma.","authors":"Adam Thomas Cristaudo, Shoma Barat, Nima Ahmadi, David Morris","doi":"10.21873/invivo.13806","DOIUrl":"10.21873/invivo.13806","url":null,"abstract":"<p><strong>Background/aim: </strong>The study examines whether DNA level mutations in the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) gene Pro-Glu-Leu-Pro-Lys (PELPK) motif differ between patients with appendiceal or colorectal adenocarcinoma. Significant differences between these two groups in correlation with development of metachronous liver metastases could help in the development of targeted therapies and preventative treatment approaches.</p><p><strong>Patients and methods: </strong>This retrospective comparative trial analysed 18 patients, 9 with appendiceal adenocarcinoma and 9 with colorectal adenocarcinoma. Genetic sequencing was conducted to detect mutations in the CEACAM5 gene PELPK motif. Data collection spanned from 2016 to 2022, with analysis completed in 2024 at a single tertiary care referral centre, where all participants underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.</p><p><strong>Results: </strong>No DNA mutations were detected in the CEACAM5 gene PELPK motif in either the study groups. Despite this, significant (but not unexpected) differences were observed between the two groups regarding operative time, peritoneal cancer index, and length of hospital stay (p=0.031, 0.001, and 0.005, respectively). Patients with colorectal adenocarcinoma also had significantly more synchronous liver metastases present at time of their peritonectomies (p=0.029).</p><p><strong>Conclusion: </strong>The absence of DNA level mutations in the CEACAM5 gene PELPK motif underscores the need for further research at the mRNA and protein levels to better understand the biological distinctions between these two groups. Future studies should focus on exploring alternative molecular pathways that may contribute to the differing clinical profiles of appendiceal and colorectal adenocarcinoma patients.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"96-101"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With <i>KIT</i> Exon 11 W557_K558 Deletion.","authors":"Hirotaka Suto, Miyuki Kawamura, Mitsunori Morita, Hideki Sakai, Takuma Onoe, Kyoko Ikeuchi, Kazuyoshi Kajimoto, Koji Matsumoto","doi":"10.21873/invivo.13857","DOIUrl":"10.21873/invivo.13857","url":null,"abstract":"<p><strong>Background/aim: </strong>Gastrointestinal stromal tumors (GISTs) are rare cancers originating from Cajal's stromal cells in the gastrointestinal tract. The most common driver mutation in these cancers is the KIT mutation. This report presents a case of response to low-dose imatinib in a patient with GIST harboring KIT exon 11 W557_K558 deletion.</p><p><strong>Case report: </strong>In June 2023, an 82-year-old male developed perineal pain. Computed tomography (CT) imaging revealed a mass measuring >9 cm, extending from the rectum to the prostate. Submucosal tumor biopsy revealed a tumor with CD117-positive and DOG1-positive spindle-shaped cells leading to a diagnosis of GIST. c-Kit gene mutation analysis detected a W557_K558 deletion in exon 11. Treatment with imatinib (400 mg/day) was initiated in late October 2023 to preserve organ function; the dose was reduced to 300 mg/day after 5 days of treatment and further reduced to 200 mg/day after 10 days, with continued treatment at this dose. The CT performed in January, April, and June 2024 showed that the rectal GIST had shrunk. The blood imatinib concentration remained at approximately 650 ng/ml from January to March 2024 and decreased to 391 ng/ml in May 2024.</p><p><strong>Conclusion: </strong>The response rate of GISTs to imatinib is influenced by genetic mutations. GIST with KIT exon 11 W557_K558 deletion is associated with a high risk of recurrence. In vitro data showed that low-dose imatinib was effective in such cases. Low-dose imatinib is a treatment option for patients with GIST harboring KIT exon 11 W557_K558 deletion who are intolerant to high-dose imatinib.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"532-538"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}